Launching Pharma or Biotech Operations in Spain: Regulatory Sequence

A pharma or biotech launch should not begin with a promise about incorporation speed or market size. The first decision is what the Spanish operation will actually do: sponsor a clinical trial, hold or support a marketing authorisation, distribute a product, employ a scientific team, contract with hospitals or only provide group services. Each model has a different regulatory perimeter.

Map the regulated roles

• Clinical trial: identify the sponsor, legal representative where required, sites, investigators, data flows and pharmacovigilance responsibilities.
• Medicinal product: distinguish marketing-authorisation, manufacturing, import, wholesale-distribution and local promotion activities.
• Research services: define ownership of results, access to samples and data, subcontracting and cross-border transfers.
• Commercial presence: decide whether a subsidiary, branch or third-party model matches the people, contracts and risk located in Spain.

Clinical-trial route

EU Regulation 536/2014 provides the European framework and CTIS is the submission environment. Spanish Royal Decree 1090/2015 complements that framework for ethics committees, the Spanish Registry of Clinical Studies and national responsibilities. AEMPS publishes current CTIS guidance and accelerated procedures; eligibility for any accelerated route must be verified rather than assumed.

Corporate and operational readiness

1. Confirm the regulated role and responsible entity.
2. Prepare the regulatory submission and evidence plan.
3. Choose the Spanish legal presence and obtain tax and employer registrations.
4. Put quality, safety, data-protection and vendor controls into contracts.
5. Document transfer pricing and ownership of intellectual property.
6. Set launch gates so commercial activity cannot precede the required authorisations.

Avoid false precision

Authorisation and incorporation timelines depend on the procedure, dossier quality, questions from authorities, bank and registry steps and whether licences are already held elsewhere in the group. Professional fees and tax incentives also depend on scope and facts. A credible plan uses dated dependencies and named owners instead of generic “six-month” or cost promises.

NRRO can coordinate Spanish corporate, tax, employment and contracting work with the client's regulatory specialists. Scientific, clinical and product authorisations remain subject to the competent authorities.

Official sources

• EU Clinical Trials Regulation 536/2014.
• Spanish Royal Decree 1090/2015 on clinical trials.
• AEMPS: CTIS and the Clinical Trials Regulation.

Reviewed on 27 August 2026.